Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 143 publications.

Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among patients with HR+/HER2– metastatic breast cancer in a privately insured US population. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 9, 2016. San Antonio, TX.

Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 9, 2016. San Antonio, TX.

Wilson M, Ziemiecki R, San Antonio B, McDade C, Thomas S, Winfree KB. Analysis of health care resource use costs in the PROCLAIM trial. Poster presented at the IASLC 17th World Conference on Lung Cancer; December 6, 2016. Vienna, Austria.

Wilson M, Wasserman M, Breton MC, McDade C, Earnshaw S, Farkouh R. Potential clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Canada. Poster presented at the 2016 Canadian Immunization Conference; December 6, 2016. Ottawa, Canada.

Li A, Dong O, Oni-Orisan A, Wiltshire T, Lee CR. Projected impact of genotype-guided optimization of medication use: an opportunity for preemptive genotyping in cardiac catheterization laboratory patients. Poster presented at the 2016 51st American Society of Health-System Pharmacists Midyear Clinical Meeting; December 5, 2016. Las Vegas, NV.

Lin HM, Davis KL, Kaye JA, Luptakova K, Gao L, Nagar S, Seal B, Mohty M. Real-world clinical outcomes by cytogenetic risk category in relapsed or refractory multiple myeloma: evidence from a cohort review in France. Poster presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2016. San Diego, CA. [abstract] Blood. 2016 Dec 2; 128(22):4784. doi: 10.1182/blood.V128.22.4784.4784

Kingsley J, Karanth S, Revere FL, Agrawal D. Cost effectiveness of screening colonoscopy depends on adequate bowel preparation rates - A modeling study. PLoS One. 2016 Dec;11(12):e0167452. doi: 10.1371/journal.pone.0167452

Korsnes JS, Goodwin BB, Murray M, Candrilli SD. Antiretroviral treatment switching and its association with economic outcomes and adverse treatment effects among commercially insured and Medicaid-enrolled patients with HIV in the United States. Ann Pharmacother. 2016 Dec;50(12):989-1000.

Barnett C, Denton BT. Developing near-optimal biomarker-based prostate cancer screening strategies. Presented at the 2016 INFORMS Annual Meeting; November 14, 2016. Nashville, TN.

Yaylali E, Farnham P, Sansom S, Hicks KA, Honeycutt A, Tucker E. Using the HOPE model for evaluating HIV interventions in the US. Presented at the 2016 INFORMS Annual Meeting; November 13, 2016. Nashville, TN.

Barnett C, Merdan S. Data analytics for optimal detection of metastatic prostate cancer. Presented at the 2016 INFORMS Annual Meeting; November 13, 2016. Nashville, TN.

Stull DE, Houghton K, Ainsworth C, Brown J, Bowman L, Boye ME. "Causal cascade" among outcomes in non-small cell lung cancer: assessing the direct and indirect effects of symptoms on health-related quality of life (HRQL) outcomes. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A748.

Boye ME, Houghton K, Stull DE. Rethinking what missing patient-reported outcome (PRO) data can teach us about outcomes and survival in oncology clinical trials. Presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria.

Lorenzo M, Hess L, Nicol S, Parikh R, Candrilli SD, Kaye JA. Advanced soft-tissue sarcoma-related treatment patterns and outcomes in elderly patients in the United States. Poster presented at the Connective Tissue Oncology Society Annual Meeting; November 2016. Lisbon, Portugal.

Le Moine J, Abeysinghe SS. Comparison of Bayesian network meta-analyses in a WinBUGS and SAS framework. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A393.

Augustin M, Krieger T, McBride D, Graham CN, Melzer N, Kneidl J, Neidhardt K. Cost-effectiveness of secukinumab as first biologic treatment for psoriasis compared with initiating other biologic therapy in Germany. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A568-9.

Elroy PW, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. Evaluating the effectiveness of treatments of opioid use disorder based on recovery outcomes: how to bridge the disconnect between clinical trial outcomes and recovery outcomes? Poster presented at the 2016 ISPOR 19th Annual European Congress; October 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A361.

Mauskopf J, Earnshaw SR, Mullins CD, Brogan A. Building a budget impact model: budget impact analysis training. Presented at the 2016 ISPOR Training Courses; November 2016. Durham, NC.

Mauskopf J, Earnshaw S. A methodological review of US budget-impact models for new drugs. Pharmacoeconomics. 2016 Nov;34(11):1111-31. doi: 10.1007/s40273-016-0426-8

Mladsi D, Ronquest N, Odom D, Miles L, Saag K. Cost-effectiveness of low-dose submicron diclofenac compared with generic diclofenac. Clin Ther. 2016 Nov;38(11):2418-29. doi: 10.1016/j.clinthera.2016.09.013

McBride D, Abuzakouk M, Balp M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K, Khalil S, Knulst A, Lacour J, Lynde C, Marsland A, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink J, Proctor C, Sussman G, Weller K, Maurer M. Comparative analysis of indirect costs associated with chronic spontaneous/idiopathicurticaria-results from the ASSURE-CSU study in 7 countries. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A573.

Bullard J, Salloum R, Eberth J, Arrington A, Cheng X, Adams SA. Timeliness of treatment initiation and associated survival following diagnosis of non-small cell lung cancer in South Carolina. Poster presented at the American Public Health Association (APHA) 2016 Annual Meeting and Expo; November 1, 2016. Denver, CO.

Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’yachkova Y, Nagar S, Candrilli SD, Kaye JA. Real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma receiving systemic therapy in the United Kingdom. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A751.

Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’yachkova Y, Nagar SP, Candrilli SD, Kaye JA. Real-world treatment patterns and survival for patients with advanced soft tissue sarcoma receiving systemic therapy in Spain. Poster presented at the Connective Tissue Oncology Society Annual Meeting; November 2016. Lisbon, Portugal.

Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’yachkova Y, Nagar SP, Candrilli SD, Kaye JA. Advanced soft tissue sarcoma: systemic treatment patterns and survival in France. Poster presented at the Connective Tissue Oncology Society Annual Meeting; November 2016. Lisbon, Portugal.

Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’yachkova Y, Nagar S, Candrilli SD, Kaye JA. Advanced soft tissue sarcoma: systemic treatment patterns and survival in Germany. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A760.

Halliday A, Hacking V, Jugl SM, Gunda P, Nikoglou E, Miles L, Graham CN. Budget impact of secukinumab for ankylosing spondylitis in the UK. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A535.

Purser M, Mladsi DM, Kaye JA. Cost-effectiveness of sonidegib versus vismodegib for the treatment of patients with locally advanced basal cell carcinoma not amenable to surgery or radiotherapy. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A731.

Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in Spain. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A410.

Bertwistle D, D'yachkova Y, Vickers AD, Hawe E, Fernandez M, Drove N, Lorenzo M, Wolowacz S. Comparative efficacy and saftey of interventions in the treatment of advanced soft tissue sarcoma: a systematic review and network meta analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A712.

Peasgood T, Brennan A, Mansell P, Elliott J, Basarir H, Kruger J. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes. Med Decis Making. 2016 Nov;36(8):1020-33. doi: 10.1177/0272989X16658660.

Cranmer H, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. To what extent does the published economic analyses of treatments for opioid use disorder capture its chronic, relapsing nature and its impact on society? Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A373.

Cranmer H, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. Health-related quality of life in opioid use disorder measured by utilities: a systematic literature review. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A387.

Barnett C, Auffenberg GB, Cheng Z, Yang F, Wang J, Miller D. Optimization of active surveillance for minimally invasive early detection of cancer progression. Poster presented at the 2016 INFORMS Annual Meeting; November 2016. Nashville, TN.

Muszbek N, Wolowacz S, Benedict A. Health economic modeling in oncology. Presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria.

Tkacz J, Brady B, Nadipelli V, Volpicelli J, Ronquest N, Un H, Ruetsch C. Opioid use disorder population: who is at risk of medication assisted treatment non-adherence? Poster presented at the 2016 AATOD Conference; October 31, 2016. Baltimore, MD.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 20th Annual International Meeting.

Earnshaw SR, Mullins CD, Brogan AJ. Budget impact analysis I: a 6-step approach. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 18th Annual European Congress.

Wolowacz S, Briggs A, Lloyd AJ, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2016 ISPOR 19th Annual European Congress; October 29, 2016. Vienna, Austria.

Wilson M, Lim J, Gandhi P, Wang C, Sander S, McDade C, Earnshaw S. Economic analysis of oral anticoagulants in the prevention of vascular events in Medicare patients with nonvalvular atrial fibrillation. Poster presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 25, 2016. Vancouver, Canada.

Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, Smyth M. Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis. PLoS One. 2016 Oct 24;11(10):e0165435. doi: 10.1371/journal.pone.0165435

Demarteau N, Standaert B, Earnshaw S. Mathematical programming modeling to optimise allocation of healthcare interventions. In: Ethgen O, Staginnus U, editors. The future of health economics. New York: NY. Routledge; 2016.

Jacobson E, Hicks KA, Yaylali E, Chen YH, Sansom S. Effects of reaching national HIV/AIDS strategy viral load suppression goal on HIV incidence, by race and ethnicity, in the United States. Presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 24, 2016. Vancouver, Canada.

White M, Hogue S, Odom D, Cooney D, Bartsch J, Hollis K, Herrem C, Silvia S. EPIPEN4SCHOOLS® survey combined analysis: a comprehensive assessment of anaphylaxis in US schools. Presented at the 2016 AAP National Conference & Exhibition; October 22, 2016. Sacramento, CA.

Suzuki O, Dong OM. PGx1: an assay for actionable genes in pharmacogenetics. Poster presented at the American Society of Human Genetics 2016 Annual Meeting; October 19, 2016. Vancouver, Canada.

Bover I, Colombo N, Korach J, Davis KL, Kaye JK, Lewis IRR, Callejo A, Gasco A. Treatment patterns and BRCA testing practice in platinum-sensitive recurrent serous ovarian cancer: a Spanish medical record review. Poster presented at the 2016 European Society for Medical Oncology Congress; October 7, 2016. Copenhagen, Denmark. [abstract] Ann Oncol. 2016 Oct 11; 27(suppl_6). doi: 10.1093/annonc/mdw374.24

Bover I, Colombo N, Korach J, Davis KL, Kaye JA, Lewis JRR. Management of platinum-sensitive recurrent serous ovarian cancer: a Spanish medical record review. Poster presented at the 2016 European Society for Medical Oncology Congress; October 7, 2016. Copenhagen, Denmark.

Wollschlaeger BA, Montejano LB, Wilson TM, Ronquest N, Nadipelli VR. How do patients diagnosed with opioid use disorders compare to the overall US population of individuals with drug use disorder? Poster presented at the 29th Annual U.S. Psychiatric & Mental Health Congress; October 2016. San Antonio, TX.

Tappenden P, Ren S, Archer R, Harvey R, James MM, Basarir H, Stevens J, Lobo A, Hoque S. A model-based economic evaluation of biologic and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure of conventional therapy. Pharmacoeconomics. 2016 Oct;34(10):1023-38. doi: 10.1007/s40273-016-0409-9.

Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract. 2016 Oct;22(5):702-16. doi: 1078155215625459